In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical studies have shown potential for increasing muscular mass and ameliorating the pathological features of dystrophic muscle by the inhibition of myostatin in various ways. However, hardly any clinical trials have proven to translate the promising results from the animal models into patient populations. We present the background for myostatin regulation, clinical and preclinical results and discuss why translation from animal models to patients is difficult. Based on this, we put the clinical relevance of future antimyostatin treatment into perspective.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001237 | PMC |
| http://dx.doi.org/10.3390/cells10030533 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy.
Int J Mol Sci
September 2024
Biohaven Pharmaceuticals Inc., New Haven, CT 06510, USA.
Spinal muscular atrophy (SMA) is a rare, genetic neurodegenerative disorder caused by insufficient production of survival motor neuron (SMN) protein. Diminished SMN protein levels lead to motor neuron loss, causing muscle atrophy and weakness that impairs daily functioning and reduces quality of life. SMN upregulators offer clinical improvements and increased survival in SMA patients, although significant unmet needs remain.
View Article and Find Full Text PDFTransglutaminase-catalyzed covalent anti-myostatin peptide depots.
Eur J Pharm Biopharm
October 2024
Institute for Pharmacy and Food Chemistry, University of Würzburg, Am Hubland, Würzburg 97074, Germany; Helmholtz-Institute for RNA-based Infection Research (HIRI), Würzburg 97070, Germany. Electronic address:
Nature realizes protein and peptide depots by catalyzing covalent bonds with the extracellular matrix (ECM) of tissues. We are translating this natural blueprint for the sustained delivery of a myostatin-inhibiting peptide (Anti-Myo), resulting in an enzyme depot established from injectable solutions. For that, we fused Anti-Myo to the D-domain of insulin-like growth factor I, a transglutaminase (TG) substrate.
View Article and Find Full Text PDFThe Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy.
Neurol Ther
February 2024
F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Introduction: Duchenne muscular dystrophy (DMD) is a genetic muscle disorder that manifests during early childhood and is ultimately fatal. Recently approved treatments targeting the genetic cause of DMD are limited to specific subpopulations of patients, highlighting the need for therapies with wider applications. Pharmacologic inhibition of myostatin, an endogenous inhibitor of muscle growth produced almost exclusively in skeletal muscle, has been shown to increase muscle mass in several species, including humans.
View Article and Find Full Text PDFArticle Synopsis
- Mutations in the COL1A1 and COL1A2 genes, which produce type I collagen, are found in 85%-90% of osteogenesis imperfecta (OI) patients, leading to weak bones and skeletal deformities.
- The study used mouse models to explore the effects of monoclonal antibodies targeting activin A and myostatin on muscle and bone in both normal and OI-affected mice.
- Results showed that while myostatin inhibition increased muscle mass in all mice, none of the treatments significantly improved bone structure, particularly in cortical bone, highlighting limitations in using these pathways for treating bone-related issues in OI.
Divergent effects of myostatin inhibition on cardiac and skeletal muscles in a mouse model of pressure overload.
Am J Physiol Heart Circ Physiol
July 2023
Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Article Synopsis
- Myostatin, a member of the TGF-β superfamily, negatively regulates muscle growth and may impact heart remodeling; its suppression's effects on pressure-overloaded hearts are uncertain.* -
- In a study with mice undergoing pressure overload (TAC), treatment with an anti-myostatin antibody (mRK35) increased muscle mass and strength but did not reduce cardiac hypertrophy or fibrosis.* -
- The findings suggest that while myostatin inhibition can help combat muscle wasting, it might not prevent harmful heart changes in conditions like cardiac vascular disease.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!